Michal Kiciński
- primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma
2026/07/21 by Alexander CJ van Akkooi, Michal Kicinski, Michal Kiciński +45
Biochemistry, Genetics and Molecular Biology · Medicine · #Cutaneous Melanoma Detection and Management #Lung Cancer Treatments and Mutations #Melanoma and MAPK Pathways